Detailed View
ELVN - Enliven Therapeutics, Inc.
Latest filing: 2026-06-30 | Reporting: gaap
Market Cap
4,351,550,464
Adj EBIT (TTM)
-124,413,000
Enterprise Value
3,456,395,464
Last Price
59.39
Earnings Yield
-3.60%
Return on Capital
-13.88%
Capital
896,062,000
1Y Price Chart
Last Price: -
1Y Change: -
Company Summary
Loading summary...
| endDate | formType | fiscalYear | Revenue | OperatingIncomeLoss |
|---|---|---|---|---|
| 2026-06-30 | 10-Q | 2026 | 0 | -37,209,000 |
| 2026-03-31 | 10-Q | 2026 | 0 | -27,823,000 |
| 2025-12-31 | 10-K (Q4 derived) | 2025 | 0 | -34,285,000 |
| 2025-09-30 | 10-Q | 2025 | 0 | -25,096,000 |
| 2025-06-30 | 10-Q | 2025 | 0 | -28,584,000 |
| 2025-03-31 | 10-Q | 2025 | 0 | -31,693,000 |
| 2024-12-31 | 10-K (Q4 derived) | 2024 | 0 | -26,896,000 |
| 2024-09-30 | 10-Q | 2024 | 0 | -27,068,000 |
Notice something wrong?
Submit a quick report with a snapshot of the values you are seeing.